Preliminary full year 2016 non-GAAP operating profit margin is expected to be 16 percent. The company expects full-year 2017 revenue of $1.065 billion, which includes approximately $10 million in year-over-year currency headwinds, and non-GAAP operating profit margin expansion of approximately 100 basis points compared with full-year 2016 (ended Dec. 31, 2016).
"We are pleased to deliver stronger than expected preliminary results for 2016, demonstrating strength across all geographies, and are excited about our outlook for 2017," said Gregory T. Lucier, chairman and CEO of NuVasive. "We remain committed to our longer-term financial performance goals and strategic initiatives that are expected to drive the company's revenue growth and operating margin expansion targets, while continuing to transform healthcare with game-changing technologies."
NuVasive anticipates full year 2016 pro forma revenue, assuming acquisitions are included in the company's financial results for the entire fiscal year, to grow 8.7 percent on a constant currency basis. Preliminary fourth-quarter 2016 revenue is expected to be approximately $265 million.
NuVasive expects full year 2017 revenue will be approximately $1.065 billion, reflecting 11.4 percent year-over-year growth, or 12.4 percent on a constant currency basis.
NuVasive Inc. develops minimally invasive, procedurally-integrated spine technologies. The San Diego, Calif.-based company's procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $811 million in revenues (2015), NuVasive has an approximate 2,200 person workforce in more than 40 countries worldwide.